Tag: GlobeNewswire

TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — Premier American Uranium Inc. (“PUR”, the “Company” or “Premier American Uranium”) (TSXV: PUR) (OTCQB: PAUIF) is pleased to report another positive update on mid-season results from the 2026 exploration drilling program at the Company’s wholly-owned Kaycee Project (“Kaycee” or the “Project”), located in the Powder River Basin of northeastern Wyoming. Initial drilling at the West Diane target has intersected uranium mineralization in six of eight holes, including 10 ft grading 0.064% eU₃O₈ in drillhole WD26-012. Following encouraging results at Rustler, PUR secured an additional 1,883 acres of mineral rights, extending the target area north and west, connecting the Rustler and Stampede claim blocks, and bringing its total land package to 31,724 acres.

As of September 25, 2026, PUR has completed 80 conventional mud-rotary drillholes for a total of 65,620 ft (30 holes and 23,660 ft since our last reporting), representing approximately 66% of the planned 100,000-ft program. Drilling is currently focused on West Diane, with a return to Rustler planned following completion of the West Diane campaign.

2026 Program Highlights

• Encouraging initial results at West Diane: Six of 8 drillholes, totaling 7,360 ft, encountered uranium mineralization at grades of 0.02% eU₃O₈ or higher (Table 1). Notably, drillhole WD26-012 intercepted 10 ft of 0.064% eU₃O₈, including 5.5 ft of 0.076% and 2 ft of 0.092% eU₃O₈ (Figure 2).
• West Diane drilling tests extensions of known mineralization: Historical drilling identified two discrete sandstone host target units within the Fort Union Formation, one of two historically productive host formations in the Smith Ranch-Highland area of the Powder River Basin. Current drilling focuses on the upper unit to better define the trend and extent of the paleochannel partially delineated by historic drilling. Infill, step-out, and confirmation holes are all planned to verify and expand areas of known uranium mineralization.
• Additional uranium intercepts at Rustler: Six of the 22 newly reported drillholes intersected uranium mineralization grading at least 0.02% eU₃O₈, including 2.5 ft grading 0.063% eU₃O₈ in RT26-121 and 3.5 ft grading 0.037% eU₃O₈ in RT26-116 (see Table 1 and Figure 3).
• Rustler mineral rights expanded by 1,883 acres: Encouraging drilling results prompted PUR to secure additional mineral rights immediately north and west of the existing claim block, extending the target area and connecting the Rustler and Stampede claim blocks.

• Two mineralized sandstone units identified at Rustler: Drilling has identified two mineralized sandstone host units, both within the lower Wasatch Formation. Uranium mineralization has been encountered in both sands, and gamma results, which indicate possible stacked roll fronts in the upper unit.
• Rustler drilling to resume across expanded target area: Drilling was paused after 45 holes while PUR secured adjacent mineral rights. With those rights now secured, drilling is expected to resume after the West Diane campaign, weather permitting.

Colin Healey, CEO of PUR commented, “Our 2026 program continues to deliver encouraging results across Kaycee. Drilling at the West Diane target has returned uranium mineralization in six of our first eight holes, including 10 ft grading 0.064% eU₃O₈, the thickest mineralized interval reported from this year’s program to date. These results provide a strong basis for follow-up drilling to test extensions of known mineralization. At Rustler, encouraging results prompted us to secure an additional 1,883 acres to the north and west, positioning us to test further exploration opportunities. With approximately two-thirds of the planned drilling complete, we look forward to advancing West Diane and returning to our expanded Rustler target area.”

Michael Harrison, Chairman, commented, “Kaycee represents one of the largest grassroots uranium exploration programs in the United States, with an expanded land package spanning approximately 31,724 acres in Wyoming’s prolific Powder River Basin. Our ongoing drilling is demonstrating the potential of this extensive land position, while the addition of strategically located mineral rights connecting the Rustler and Stampede claim blocks strengthens our exploration footprint. PUR is focussed on adding essential uranium resources in the United States.”

Table 1. Kaycee Significant Intercepts – August 18 to September 25, 2026

Target Area	Drillhole	Intercept	From (ft)	To (ft)	Thickness (ft)	eU₃O₈%
Rustler	RT26-106	intersected	412.5	413	0.5	0.022
	RT26-112	intersected	386.5	387.5	1	0.021
		and	700	701	1	0.032
	RT26-115	intersected	648	650.5	2.5	0.023
	RT26-116	intersected	416	419.5	3.5	0.037
	RT26-119	intersected	401.5	402.5	1	0.023
		and	426	427	1	0.022
	RT26-121	intersected	427.5	430	2.5	0.063
		including	428	429.5	1.5	0.081
		including	428.5	429	0.5	0.1
West Diane	WD26-011	intersected	898.5	901.5	3	0.081
		including	899	901	2	0.108
		including	899.5	900.5	1	0.141
		and	902	904	2	0.039
		including	902.5	903.5	1	0.053
	WD26-012	intersected	859.5	869.5	10	0.064
West Diane		including	860.5	862	1.5	0.078
		including	863	868.5	5.5	0.076
		including	864	866	2	0.092
		including	864.5	865	0.5	0.102
	WD26-013	intersected	826	831	5	0.063
		including	826.5	828.5	2	0.096
		including	827	828	1	0.119
		and	839	840.5	1.5	0.02
	WD26-014	intersected	833.5	835	1.5	0.025
	WD26-015	intersected	814	815	1	0.021
	WD26-018	intersected	618	620	2	0.033
		and	633	635	2	0.031

Notes: Drill holes reported here encountered uranium mineralization at or above a cut-off grade of 0.02% eU₃O₈. Uranium grades cited were calculated from gamma-ray logs measured by Hawkins CBM Logging of Casper, Wyoming, and the cited grades are “equivalent” (“e”) grades of U₃O₈. Hawkins CBM Logging’s geophysical probe was calibrated at the US Department of Energy’s Casper, Wyoming test pits in August 2026. No corrections were made for radiometric disequilibrium. Numerous comparisons of eU₃O₈ and chemical assays of PRB core samples indicate that eU₃O₈ is a reasonable indicator of the actual uranium assay. All drill holes are vertical in orientation and the geologic units hosting the uranium mineralization are generally very flat lying, therefore reported thicknesses are considered to approximate or modestly exceed true thicknesses.

Figure 1. Kaycee Project Key Targets in 2026

Figure 2. West Diane 2026 Drill Holes 

Figure 3. Rustler 2026 Drill Holes

Kaycee Project

The Kaycee Project in Wyoming’s Powder River Basin (PRB) consists of over 42 square miles of mineral rights over a 36-mile mineralized trend hosting more than 110 miles of identified roll fronts (Figure 4). The Project is believed to be the only project in the PRB where all three known historically productive sandstone formations (Wasatch, Fort Union, and Lance) are mineralized and potentially accessible for ISR extraction. PUR’s exploration team are undertaking the largest grass-roots ISR drill program in the United States, with upwards of 400,000 ft of drilling completed since 2023.

PUR anchors one of the strongest exploration portfolios in Wyoming, combining its Cyclone Project in the Great Divide Basin with Kaycee to drive one of the largest ongoing drilling programs in the state and significantly expand its presence in both of the state’s major ISR-amenable uranium districts.

Figure 4. PUR’s Wyoming exploration portfolio, highlighting the Kaycee Project in the Powder River Basin and the Cyclone Project in the Great Divide Basin.

Qualified Person Statement

The scientific and technical information contained in this news release was reviewed and approved by J.J. Brown, P.G., SME-RM, PUR’s Vice President Exploration, who is a “Qualified Person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Ms. Brown has verified the data disclosed in this news release, including sampling, analytical, and test data underlying the information contained herein.

The drilling results cited in this news release were derived from conventional mud rotary drill holes and continuously recorded geophysical responses (gamma-ray, spontaneous-potential, and single point resistivity) from a borehole geophysical probe. All drill holes are vertical in orientation and the geologic units hosting the uranium mineralization are generally very flat lying, therefore reported thicknesses are considered to approximate or modestly exceed true thicknesses. Grades of mineralization reported were calculated from the gamma-ray logs following a procedure that was first developed in the early 1960s and is standard practice in the uranium industry. The borehole geophysical logging was carried out by Hawkins CBM of Casper, Wyoming, a highly experienced and skilled geophysical contractor with a well-established history of providing reliable and accurate data.

Other information regarding the Company’s Kaycee Project, including with respect to the Quality Assurance and Quality Control measures applied during the work program can be referenced from the “Technical Report for NI 43-101 Kaycee Uranium Project, Johnson County, Wyoming USA”, dated September 21, 2025, which is available under the Company’s profile on SEDAR +, at www.sedarplus.ca.

About Premier American Uranium Inc.

Premier American Uranium is focused on consolidating, exploring, and developing uranium projects across the United States to strengthen domestic energy security and advance the transition to clean energy. The Company’s extensive land position spans five of the nation’s top uranium districts, with active work programs underway in New Mexico’s Grants Mineral Belt and Wyoming’s Great Divide and Powder River Basins.

Backed by strategic partners including Sachem Cove Partners, IsoEnergy Ltd., Mega Uranium Ltd., and other leading institutional investors, PUR is advancing a portfolio supported by defined resources and high-priority exploration and development targets. Led by a distinguished team with deep expertise in uranium exploration, development, permitting, operations, and uranium-focused M&A, the Company is well positioned as a key player in advancing the U.S. uranium sector.

For More Information, Please Contact:

Premier American Uranium Inc.
Colin Healey, CEO

info@premierur.com
Toll-Free: 1-833-223-4673
Twitter: @PremierAUranium
www.premierur.com

Neither TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, statements with respect to, additional exploration activities planned for 2026, the anticipated results thereof and the anticipating timing for reporting of such results; future prospects for exploration; expectations regarding the transition to clean energy in the US; and other activities, events or developments that are expected, anticipated or may occur in the future. Generally, but not always, forward-looking information and statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof.

Forward-looking information and statements are based on our current expectations, beliefs, assumptions, estimates and forecasts about PUR’s business and the industry and markets in which it operates. Such forward-information and statements are based on numerous assumptions, including among others, that the results of planned exploration activities are as anticipated, the price of uranium, the anticipated cost of planned exploration activities, the completion, timing and results of planned exploration activities being consistent with expectations, the anticipated mineralization being consistent with expectations, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms, that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Company’s planned exploration activities will be available on reasonable terms and in a timely manner. Although the assumptions made by PUR in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate.

Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual results, performances and achievements of Premier American Uranium to differ materially from any projections of results, performances and achievements of Premier American Uranium expressed or implied by such forward-looking information or statements, including, among others: limited operating history, negative operating cash flow and dependence on third party financing, uncertainty of additional financing, delays or failure to obtain required permits and regulatory approvals, changes in mineral resources, no known mineral reserves, aboriginal title and consultation issues, reliance on key management and other personnel; potential downturns in economic conditions; availability of third party contractors; availability of equipment and supplies; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry; changes in laws and regulation, competition, and uninsurable risks and the risk factors with respect to Premier American Uranium set out in the documents of PUR filed with the Canadian securities regulators and available under PUR’s profile on SEDAR+ at www.sedarplus.ca.

Although PUR has attempted to identify important factors that could cause actual actions, events or results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. PUR undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws.

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8aa9df2a-b315-44eb-b746-7f0ccdd22b0e

https://www.globenewswire.com/NewsRoom/AttachmentNg/b52dd8f3-0f2d-4c7b-8f3f-2ac6c3be6a62

https://www.globenewswire.com/NewsRoom/AttachmentNg/b7f75b68-d17c-400e-8b57-50bd8581b452

https://www.globenewswire.com/NewsRoom/AttachmentNg/e25898c5-c279-47f5-9c44-601fa374885b

Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response

MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) — BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced the publication of the first peer-reviewed head-to-head study comparing Northstar Response®, a tissue-free, methylation-based liquid biopsy assay utilizing patented single-molecule counting technology to measure the absolute number of circulating tumor DNA (ctDNA) molecules, with a commercially available tumor-informed ctDNA assay for advanced cancer patients undergoing treatment. The study found that Northstar Response tracked disease dynamics on par with or better than the tumor-informed comparator, without requiring tissue sequencing.

The retrospective real-world study, published in The Journal of Liquid Biopsy, evaluated 169 paired samples from 61 patients, with 71 samples from 36 patients that had sequential concurrent draws for the two assays collected within seven days of each other. Quantitative results, after patient-specific baseline normalization, across repeated measurements were shown to be closely aligned (conditional R² = 0.97). Across evaluable sequential pairs, the two approaches reached the same conclusion of the change in tumor burden direction in 94% of cases (67 of 71).

Importantly, in all of the divergent cases, Northstar Response results were concordant with the ground truth substantiated by imaging and/or biopsy, indicating that the tumor-informed results were either false-positives or false-negatives. For instance, Northstar Response detected progression in cases where the tumor had evolved since the original biopsy, including a case of hormone receptor conversion in advanced breast cancer. Together, the cases illustrate the particular value of tumor-agnostic monitoring to track tumor burden and evolution.

“The ability to combine cancer-associated methylation with single-molecule precision to track changing tumor signal directly from blood is game-changing, as so many patients in the clinic will benefit,” said Vaia Florou, MD, MS, Associate Professor Division of Oncology at the Huntsman Cancer Institute at the University of Utah. “These results showing that a standardized assay can deliver precise longitudinal monitoring without tissue dependency are incredibly relevant for those of us practicing on the frontlines of cancer care.”

Since Northstar Response is not limited to alterations selected from an earlier tissue sample at a fixed point in time, it can capture clinically meaningful changes in disease biology that emerge under treatment pressure. Northstar Response’s simplified workflow can also significantly accelerate the start of molecular monitoring of treatment, potentially by weeks, and enable testing when tissue is unavailable, inadequate, or difficult to biopsy.

“Not only does Northstar Response deliver highly accurate insight into how disease is evolving during treatment, but it also has the added advantage of a streamlined and efficient workflow that can bring molecular testing to more patients,” said Allen Chen, MD, Vice President of Oncology Clinical Development and Medical Affairs at BillionToOne. “Treatment monitoring must be both reliable and practical for it to be effective in routine oncology care. These results show that clinicians do not need to compromise one for the other.”

About Northstar Response

Northstar Response is BillionToOne’s tissue-free, methylation-based ctDNA assay purpose-built for treatment response monitoring in patients with cancer. Powered by the company’s patented QCT™ molecular counting platform — the only multiplex technology capable of counting DNA molecules at the single-molecule level — Northstar Response quantifies tumor burden through serial blood draws with no dependence on tumor tissue at any stage of the patient journey.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company’s proprietary single-molecule next-generation sequencing (smNGS) platform is the only multiplex technology that can detect and precisely quantify genetic targets at the physical limit of detection, down to the single DNA molecule. Enabled by Quantitative Counting Templates™ (QCTs™), the platform quantifies disease-related DNA fragments with single base-pair resolution, providing absolute quantification. For more information, visit www.billiontoone.com.

Disclaimer

Northstar Response may produce false-positive or false-negative results. Test results are not a guarantee of the presence or absence of disease or treatment response and should not be used as the sole basis for medical decision-making. Results should be interpreted in conjunction with the patient’s clinical presentation, radiographic findings, and other diagnostic information. Northstar Response is intended to complement, not replace, standard clinical and radiographic assessment of disease status. Northstar Response is a laboratory-developed test (LDT) performed in a CLIA-certified and CAP-accredited laboratory. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test performance may vary based on factors including cancer type, disease burden, treatment, and specimen characteristics.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding the clinical performance of Northstar Response. These statements are based on management’s current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne’s control. These and additional risks and uncertainties could affect BillionToOne’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include, but are not limited to, those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in BillionToOne’s Annual Report on Form 10K, most recently filed Quarterly Report on Form 10-Q, and other filings we make with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne’s views as of any date subsequent to the date of this press release.

Reference

Choksi A, Varga MG, Farmer T, et al. Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors. The Journal of Liquid Biopsy. Volume 14, 2026, 100669.

Media Contact

Rachel Ford Hutman
rachel@fordhutmanmedia.com

TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — (TSXV: NXLV) – NexLiving Communities Inc. (“NexLiving” or the “Company”), a Canadian multi-family real estate company focused on secondary markets across Canada, which has delivered a 20% compound annual growth rate in FFO per share from 2022 to Q2 2026 through disciplined acquisitions, operational improvements and capital recycling, is pleased to announce that it will be participating in the 2026 Cantech Investment Conference, taking place on Thursday, October 8, 2026, at the Arcadian Loft in Toronto, Ontario.

Stavro Stathonikos, President & CEO, will present an overview of the Company’s business, recent operational and financial milestones, growth strategy and outlook. Management will also participate in one-on-one meetings with investors throughout the conference.

The Cantech Investment Conference, hosted by Cantech Letter, features company presentations and one-on-one meetings with investors.

Investors interested in meeting with NexLiving Communities Inc. during the conference are encouraged to contact Cantech Letter to arrange a one-on-one meeting.

Investor registration remains open. Additional information, the conference agenda and registration details are available here.

About the Company

NexLiving Communities Inc. (TSXV: NXLV) is a Canadian multi-family real estate company focused on acquiring, operating, and growing a portfolio of recently built and refurbished, highly leased residential properties in secondary markets across Canada.

NexLiving is developing a new standard in Canadian multi-family real estate, with a focus on long-term tenants who value proximity to healthcare, nature trails, parks, public transportation, and convenient services, and who hold modern, condo-style expectations of their homes and communities. The Company’s portfolio consists of Class A, low- and mid-rise buildings featuring modern and high-end finishes, elevators, heated underground parking, and a range of amenities designed to support a hassle-free, maintenance-free lifestyle. NexLiving aims to deliver exceptional living experiences to our residents and provide comfortable, affordable housing solutions that cater to a wide range of demographics. The Company currently owns 2,054 units in New Brunswick, Quebec, Ontario and Manitoba and has 108 units under construction in Ottawa.

NexLiving is executing a disciplined and accretive growth strategy acquiring high-quality assets with strong day-one cash flow, optimizing operations, and recycling capital into higher-yielding opportunities. The Company continues to evaluate both acquisition targets and non-core asset dispositions as part of its ongoing portfolio optimization strategy, with a scalable growth pipeline extending well beyond 2026.

For more information about NexLiving, please refer to our website at www.nexliving.ca and our public disclosure at www.sedarplus.ca.

Forward-Looking Statements

This news release contains forward-looking information within the meaning of applicable Canadian securities laws (“forward-looking statements”). All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “projects”, “estimates”, “forecasts”, “intends”, “continues”, “anticipates”, or “does not anticipate” or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements contained in this news release include, but are not limited to, the Company’s participation in the Cantech Investment Conference and the Company’s growth strategy and outlook. Such forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. These forward-looking statements reflect the current expectations of the Company’s management regarding future events and operating performance, but involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual events could differ materially from those projected herein and depend on a number of factors. These risks and uncertainties are more fully described in regulatory filings, which can be obtained on SEDAR+ at www.sedarplus.ca, under NexLiving’s profile, as well as under the Risks and Uncertainties section of the MD&A released on August 12, 2026. Although forward-looking statements contained in this news release are based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release. Except as required by applicable securities laws, the Company does not undertake, and specifically disclaims, any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.

Non-IFRS Financial Measures

The Company prepares and releases unaudited consolidated interim financial statements and audited consolidated annual financial statements prepared in accordance with IFRS. In this news release, as a complement to results provided in accordance with IFRS, NexLiving discloses FFO per share, a financial measure not recognized under IFRS which does not have a standard meaning prescribed by IFRS (a “Non-IFRS Measure”). This Non-IFRS Measure is further defined and discussed in the MD&A dated August 12, 2026, which should be read in conjunction with this news release. Since this measure is not recognized under IFRS, it may not be comparable to similar measures reported by other issuers. The Company presents this Non-IFRS Measure because management believes it is a relevant measure of the ability of NexLiving to earn revenue and to evaluate its performance and cash flows. A reconciliation of this Non-IFRS Measure is included in the MD&A dated August 12, 2026. The Non-IFRS Measure should not be construed as an alternative to net income (loss) or cash flows from operating activities determined in accordance with IFRS as an indicator of the Company’s performance.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information please contact:
Stavro Stathonikos
sstathonikos@nexliving.ca
647-847-2030

Highlights:

• CS26-096: two (2) separate intervals, including:
  • 134.5 m at 1.20 % Li₂O (starting at surface), and
  • 101.6 m at 1.02 % Li₂O
  • The entire 101.6 m interval in hole-96 is outside of the conceptual pit-shell defined in the April-2026 MRE.  

• CS26-095: 10 separate intervals, including:
  • 70 m at 1.28 % Li₂O,
  • 31.3 m at 1.00 % Li₂O, and
  • 25.7 m at 1.33 % Li₂O.
• CS26-094: two (2) separate intervals, including:
  • 29.2 m at 1.53 % Li₂O, and
  • 19.3 m at 1.84 % Li₂O.
• A total of 19,521 m over 43 drill holes has been completed to date during the 2026 Summer Drill Program and five (5) drill rigs continue to operate at Cisco.
• The Company expects to publish its inaugural Preliminary Economic Assessment on the Cisco Lithium Project in Fall-2026

VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Q2 Metals Corp. (TSX.V: QTWO | OTCQB: QUEXF | FSE: 458) (“Q2” or the “Company”) is pleased to report on analytical results from the 2026 summer drill program (the “2026 Summer Drill Program”) at the Company’s Cisco Lithium Project (the “Project” or the “Cisco Project”), located within the greater Nemaska traditional territory of the southernmost portion of the Eeyou Istchee, James Bay region of Quebec, Canada.

The Cisco Deposit is located just 6.5 kilometres (“km”) from the paved, all-season Billy Diamond Highway, providing strategic year-round direct access to rail infrastructure in the Town of Matagami, just ~150 km to the south.

The results reported herein represent 1,090 metres (“m”) of drilling over three (3) drill holes.

2026 Exploration Program Update

Crews were mobilized to the Cisco Project in May, with the drill campaign commencing in June, targeting infill, extension and exploration drilling across the main deposit area. Drilling is anticipated to continue until mid-December. Five (5) drill rigs are currently operating at the Cisco Project with two (2) drill rigs focusing on infill drilling of the Cisco Deposit and three (3) focused on expansion and exploration drilling to the north, south and east.

The Inferred Mineral Resource Estimate on the Cisco Project, announced on April 20, 2026 and filed June 03, 2026, outlines a pit-constrained resource of 270 million tonnes (“Mt”) grading 1.36% Li₂O at a 0.4% Li₂O cut-off grade and an additional underground-constrained resource of 24 Mt grading 1.34% Li₂O Inferred at a 0.7% Li₂O cut-off grade (together, the “Cisco Deposit”). The Cisco Deposit hosts a total Inferred Mineral Resource of 295 Mt grading 1.36% Li₂O (the “April-2026 MRE”).

The April-2026 MRE was based on 33,343 m of drilling across 75 holes completed up to December 15, 2025. The April-2026 MRE will inform the Preliminary Economic Assessment (“PEA”) currently being prepared by BBA Inc. and anticipated to be published in Fall-2026.

To date, a total of 61,045 m has been drilled at the Cisco Project across 137 holes.

Analytical results on drill holes are announced as they are received and validated. All drilling completed in 2026 and early 2027 will be included in an update to the April-2026 MRE.

Regional Exploration

Alongside the 2026 Summer Drill Program, extensive regional greenfield exploration, including indicator mineral till sampling and geochemical soil sampling, expanded prospecting and mapping and surface channel sampling commenced in May and is ongoing. The objective of the regional program is to collect information that could potentially lead to new discoveries at the Cisco Project. The channel sampling is designed to collect resource-definition-quality surface data to complement the drilling program and enhance geological interpretation of the deposit.

Analytical results from the mineral till and soil sampling and channel sampling will be reported when received and validated.

Sage McCallum, Q2 Metals Vice President, Exploration said, “Drill hole-96 is another clear example of how generous the Cisco Project continues to be. We’ve now extended the previously known mineralization of the Cisco Deposit by an additional 100 metres to the north at a shallow depth while also defining a significant interval outside of the conceptual pit-shell outlined in the April-2026 MRE. It’s been an exceptionally active summer at the Cisco Project – the team has maintained a strong pace, drilling roughly 20,000 metres since mid-June, alongside ongoing regional work to evaluate additional targets beyond those originally evaluated in 2024 and 2025.”

“The April-2026 MRE quantified the exceptional scale of the Cisco Deposit, while the adjacent Exploration Target underscores the considerable upside potential still to be realized. This summer’s drill program successfully extended significant near surface mineralization to the north, beyond the limits of the April-2026 MRE and reinforced that Cisco remains opens in all directions with meaningful growth potential,” said Alicia Milne, Q2 Metals President and CEO.

“As our exploration work continues, our focus is firmly on the PEA, a pivotal milestone in Cisco’s transition from pure exploration toward a project that can be measured and valued against global peers. With $70.9 million on our balance sheet as of August 31, 2026, we are well-capitalized to continue to deliver across all major workstreams and unlock Cisco’s full potential as a globally significant project.”

Figure 1. Updated Map of Recent Drill Holes at Cisco Project

Drill Results Discussion

Drill hole-95

• Drill hole-95 successfully confirmed the main zone of the Cisco Deposit at its western margin with 10 separate spodumene pegmatite intervals up to 70 m at 1.28 % Li₂O.

Drill hole-96

• Drill hole-96 successfully extended the previous mineralization by 100 m to the north of drill hole-77 (announced June 02, 2026) which encountered 107.8 m of 1.74% Li₂O.  
• Importantly, the 134.5 m interval started at-surface and vertically continued to approximately 100 metres below surface. The lower 101.6 m interval is entirely outside of the conceptual pit-shell defined in the April-2026 MRE.

Figure 2. Cross-Section Including Drill Hole-96

Summary of Analytical Results

Table 1. Summary of Analytical Results of Drill Holes at Cisco Project

All intervals of greater than 5 m of core-length and greater than 0.30% Li₂O are included in Table 1. Internal dilution of non-pegmatite material was limited to intervals of less than 5 m. No specific grade cap or lower cut-offs were used during grade and width calculations. All intervals are reported as core widths and mineralized intervals in all the holes drilled thus far are not representative of the true width as the modelled pegmatite zones are being refined with every additional hole.

Drill Hole Collar Information

The summary of drill holes including basic location and dip/azimuth is detailed below (Table 2).

Table 2. Summary of Drill Hole Collar Information, Cisco Project

Sampling, Analytical Methods and QA/QC Protocols

All drilling was conducted using diamond drill rig with NQ sized core and all drill core samples are shipped to SGS Canada’s preparation facility in Val D’Or, Quebec, for standard sample preparation (code PRP92) which includes drying at 105°C, crushing to 90% passing 2 mm, riffle split 500 g, and pulverize 85% passing 75 microns. The pulps are then shipped by air to SGS Canada’s laboratory in Burnaby, BC, where the samples are homogenized and subsequently analyzed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (code GE_ICM91A50). The reported Li grade will be multiplied by the standard conversion factor of 2.153 which results in an equivalent Li₂O grade. Drill core was saw-cut with half-core sent for geochemical analysis and half-core remaining in the box for reference. The same side of the core was sampled to maintain representativeness.

A Quality Assurance / Quality Control (QA/QC) protocol following industry best practices was incorporated into the sampling program. Measures include the systematic insertion of quartz blanks and certified reference materials (CRMs) into sample batches at a rate of approximately 5% each. Additionally, analysis of pulp-split and reject-split duplicates was completed to assess analytical precision. The Qualified Person (“QP”) has verified the QA/QC results of the analytical work.

Qualified Person 

Neil (Sage) McCallum, B.Sc., P.Geol, is a QP as defined by NI 43-101, and a registered permit holder with the Ordre des Géologues du Québec and member in good standing with the Professional Geoscientists of Ontario. Neil (Sage) McCallum is a director and the Vice President Exploration for Q2 Metals and has reviewed and approved the technical information in this news release. 

Upcoming Events

Q2 will be attending the following conferences and events: 

Ignite Conference	Hong Kong	October 14-15, 2026
IMARC	Sydney, Australia	October 27-29, 2026
XPLOR	Montreal, Quebec	November 2-5, 2026
Canaccord Genuity Australia Metals & Mining Conference	Noosa, Australia	November 11-13, 2026
Québec Mines + Énergie	Quebec City, Quebec	November 17-19, 2026
121 Conference	London, UK	November 23-24, 2026

ABOUT Q2 METALS CORP. 

Q2 Metals is a Canadian mineral exploration company focused on advancing the Cisco Lithium Project which is located within the greater Nemaska traditional territory of the Eeyou Istchee, James Bay region of Quebec, Canada. The Cisco Deposit is strategically situated just 6.5 km from the Billy Diamond Highway, providing access to rail infrastructure in the Town of Matagami, ~150 km to the south, with connections to deep seaports beyond.

The current Inferred Mineral Resource Estimate on the Cisco Deposit outlines a pit-constrained resource of 270 Mt grading 1.36% Li₂O at a 0.4% Li₂O cut-off grade and an additional underground-constrained resource of 24 Mt grading 1.34% Li₂O Inferred at a 0.7% Li₂O cut-off grade. Together, these support a combined inferred mineral resource of 295 Mt grading 1.36% Li₂O. The Cisco Deposit remains open along strike, with several additional high-priority targets identified across the broader 41,253 ha project area.

The 2026 exploration program is ongoing, with a primary focus on infill drilling aimed at advancing the resource toward an indicated resource classification as well as targeted expansion drilling and regional exploration designed to evaluate high-priority targets surrounding the Cisco Deposit and across the broader project area.

FOR FURTHER INFORMATION, PLEASE CONTACT: 

Alicia Milne	Jason McBride	Chris Ackerman
President & CEO	Investor Relations Manager	Corporate Development
AMilne@Q2metals.com	JMcBride@Q2metals.com	CAckerman@Q2metals.com

Telephone: 1 (800) 482-7560         
E-mail: info@Q2metals.com  
www.Q2Metals.com 

Social Media: 
Twitter, LinkedIn, Facebook, and Instagram 

Forward-Looking Statements 

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian legislation. Forward-looking statements are typically identified by words such as: “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “would”, “will”, “potential”, “scheduled” or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Accordingly, all statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, any statements or plans regard the geological prospects of the Company’s properties and the future exploration endeavors of the Company. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions. 

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date specified in such statement. Forward looking statements in this news release may include, but are not limited to, drilling results on the Cisco Project and inferences made therefrom, the conceptual nature of an exploration target on the Cisco Project, the potential scale of the Cisco Project, the focus of the Company’s current and future exploration and drill programs, the scale, scope and location of future exploration and drilling activities, the Company’s expectations in connection with the projects and exploration programs being met, the Company’s objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, variations in ore grade or recovery rates, changes in project parameters as plans continue to be refined, unsuccessful exploration results, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, reallocation of proposed use of funds, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, delays in receiving government approvals, unanticipated environmental impacts on operations and costs to remedy same. Readers are cautioned that mineral exploration and development of mines is an inherently risky business and accordingly, the actual events may differ materially from those projected in the forward-looking statements. Additional risk factors are discussed in the section entitled “Risk Factors” in the Company’s Management Discussion and Analysis for its recently completed fiscal period, which is available under Company’s SEDAR profile at www.sedarplus.com.   

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/6e9633ab-1072-4c20-991a-ed077877a9c1

https://www.globenewswire.com/NewsRoom/AttachmentNg/28508a2c-6662-43df-8e97-a0699f63c1b5

https://www.globenewswire.com/NewsRoom/AttachmentNg/2d213334-b4ce-4eb7-918a-88c0d0e90faa

https://www.globenewswire.com/NewsRoom/AttachmentNg/93022e0a-498e-4fb7-86d2-4a78f28cac77

Final close of Funds 4 and 5 Series 2 takes total capital raised to full target of US$1 billion, with a 99% repeat investment rate

SYDNEY, Oct. 07, 2026 (GLOBE NEWSWIRE) — Omni Bridgeway Limited (ASX: OBL), the world’s leading alternative asset manager dedicated to legal finance, today confirmed the final close of its Funds 4 and 5 Series 2 capital raise, reaching in full the targeted US$1 billion across both funds.

The Series 2 capital raise further broadens and diversifies Omni Bridgeway’s institutional investor base, while maintaining a strong reinvestment rate. Investors representing 99% of Series 1 commitments have reinvested in Series 2, with over 50% of Series 2 capital committed by Series 1 investors. The investor base comprises global top-tier institutional investors.

The close increases assets under management to A$5.9 billion (US$4.2 billion). It comes as Omni Bridgeway marks its 40th year as a global specialist in legal assets and its 25th year listed on the ASX.

Key facts

• Strategy: Investments in legal assets, diversified globally by jurisdiction, area of law and investment style.
• Total fund size: US$1 billion across Funds 4 and 5 Series 2.
• Alignment: Approximately 20% Omni Bridgeway GP co-investment in Series 2.
• Repeat participation: Investors representing 99% of Series 1 commitments have reinvested, with >50% of Series 2 capital committed by repeat investors.
• Platform track record: As at 30 June 2026, 822 completed investments at a portfolio-wide 2.4x multiple of invested capital (MOIC) across multiple decades and economic cycles.
• Fund-level returns, vintage analysis and the Group’s forward capital strategy are set out in Omni Bridgeway’s FY26 results presentation and analyst data pack, available at omnibridgeway.com/investors.

Raymond van Hulst, Managing Director and CEO of Omni Bridgeway, said:

“In legal finance, institutional capital is consolidating around mature, scaled managers with proprietary origination and work-out capability, and a track record of disciplined underwriting that has performed through multiple economic cycles.”

“Our successful close, the 99% reinvestment rate, and the sophisticated institutional quality of our investment base reflect our leading position within legal finance.”

“Funded parties increasingly and rightly focus on capital availability, long-term stability and commitment authority. Every dollar we commit is matched by dedicated fund capital earmarked to that matter. Omni Bridgeway is the sole decision-maker, and the availability of our capital commitment is not exposed to the outcome of other portfolio investments, capital market conditions, third-party underwriting or syndication. Counterparties increasingly recognize and value these differentiators – and accordingly assign a premium to our capital.”

“The US$1 billion raised in connection with Funds 4 and 5 Series 2 sits alongside a broader capital strategy, with sidecar capital and structured finance solutions continuing to expand alongside our core funds, supporting Omni Bridgeway’s aim of further scaling and diversifying its platform.”

Investor and Media Contacts

Media

Naomi Barber, Director, Business Development & Marketing
+61 421 371 844, nbarber@omnibridgeway.com
Management is available for interviews

Investor Relations

Nathan Kandapper, Global Head of Corporate Development and Investor Relations
+61 403 941 502, nkandapper@omnibridgeway.com

ABOUT OMNI BRIDGEWAY

Omni Bridgeway is the world’s leading alternative asset manager dedicated to legal finance, with over A$5.9 billion in assets under management across multiple funds. Founded in 1986 and listed on the ASX since 2001, Omni Bridgeway has pioneered the industry and has a unique track record of consistent outperformance across multiple decades and economic cycles. With a team of approximately 160 professionals operating in over 20 locations and 15 countries, Omni Bridgeway is the largest and most diversified institutional platform for primary origination, underwriting and management of legal assets and risk, across all relevant jurisdictions and areas of law.

• Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005
• Cadrenal has received strong interest from potential strategic partners
• Cadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions

PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio.

The initiative builds on Cadrenal’s ongoing strategic partnering discussions and will evaluate a broad range of potential transactions involving the Company and its clinical- and development-stage programs, including CAD-1005, tecarfarin, frunexian, and CAD-2000, the Company’s second-generation 12-LOX platform. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions.

Cadrenal has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor in connection with the process.

“Our pipeline has reached critical clinical and regulatory maturity, anchored by our recent alignment with the FDA on the Phase 3 development pathway for CAD-1005,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “Having received strong interest from potential strategic partners, we believe a formal strategic process provides the appropriate framework to evaluate opportunities across our portfolio and determine the paths that can maximize value for our shareholders while advancing these programs for patients.”

There can be no assurance that the strategic process will result in any transaction or other strategic outcome. Cadrenal does not intend to provide updates on the process unless and until its Board of Directors approves a specific transaction or course of action, or the Company otherwise determines that disclosure is appropriate or required.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company’s portfolio comprises clinical- and development-stage programs addressing significant unmet needs in critical care cardiology and orphan cardiovascular conditions.

CAD-1005 is a first-in-class 12-lipoxygenase (12-LOX) inhibitor in development to treat heparin-induced thrombocytopenia (HIT), a serious immune-mediated thrombotic disorder. CAD-1005 is designed to selectively inhibit 12-LOX, a pathway involved in platelet immune activation and thrombo-inflammatory signaling in HIT. The program has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. Cadrenal has received FDA feedback on the pathway for a Phase 3 registration study of CAD-1005 in HIT.

Tecarfarin is a Phase 3-ready oral vitamin K antagonist under development for patients requiring chronic anticoagulation, including those with end-stage kidney disease, atrial fibrillation, and implanted left ventricular assist devices. Tecarfarin has received FDA Orphan Drug and Fast Track designations for certain indications.

Frunexian is an investigational parenteral small-molecule Factor XIa inhibitor under development for acute and critical care settings, including major cardiac surgery.

CAD-2000 is a preclinical, next-generation, orally bioavailable 12-lipoxygenase (12-LOX) inhibitor under development as an outpatient Immunology & Inflammation (I&I) platform. CAD-2000 targets adipo-inflammatory signaling and systemic lipid-driven inflammation to address chronic metabolic and cardiorenal disorders. Positioned as an oral follow-on companion to CAD-1005, the asset is optimized for broad, large-market chronic inflammatory indications, including obesity-driven systemic inflammation, metabolic-associated steatohepatitis (MASH), and chronic cardiorenal diseases. It offers potential therapeutic synergy when combined with existing blockbuster metabolic regimens. For more information, please visit www.cadrenal.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include, among other things, statements regarding the Company’s strategic process; the potential timing, structure, benefits and outcome of that process; the possibility of any licensing transaction, asset sale, partnership, business combination or other strategic transaction; the clinical development, regulatory approval and commercialization of CAD-1005, tecarfarin, frunexian, CAD-2000 and the Company’s other programs; and the potential benefits and market opportunities associated with the Company’s product candidates.

Forward-looking statements may be identified by words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

These risks and uncertainties include, without limitation, the possibility that the strategic process may not result in a transaction; the Company’s ability to identify, negotiate and complete any strategic transaction on acceptable terms or at all; potential disruption to the Company’s business during the strategic process; the Company’s need for additional capital and ability to obtain financing on acceptable terms; risks associated with clinical development and regulatory approval; the Company’s ability to develop and commercialize its product candidates; the Company’s ability to maintain the listing of its common stock on The Nasdaq Capital Market; and the other risks described under the heading “Risk Factors” in Cadrenal’s filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date of this press release, and Cadrenal undertakes no obligation to update them except as required by applicable law.

For more information, please contact:

Cadrenal Therapeutics, Inc.
Quang X. Pham, CEO
(904) 300-0701
press@cadrenal.com

TALLAHASSEE, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — Capital City Bank Group, Inc. (NASDAQ: CCBG) announced today that it will release third quarter 2026 results on Tuesday, October 20, 2026, before the market opens. Upon release, investors may access a copy of the earnings results at the Company’s Investor Relations website, investors.ccbg.com.

About Capital City Bank Group, Inc.
Capital City Bank Group, Inc. (NASDAQ: CCBG) is one of the largest publicly traded financial holding companies headquartered in Florida and has approximately $4.5 billion in assets. We provide a full range of banking services, including traditional deposit and credit services, mortgage banking, asset management, trust, merchant services, bankcards, and securities brokerage services. Our bank subsidiary, Capital City Bank, was founded in 1895 and has 62 banking offices, 27 mortgage offices and 107 ATMs/ITMs in Florida, Georgia and Alabama. For more information about Capital City Bank Group, Inc., visit www.ccbg.com. 

For Information Contact:
Jep Larkin
Executive Vice President and Chief Financial Officer
850.402.8450

Conference Call on Wednesday, October 14, 2026 at 10:30 am ET

MILTON, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) — Sono-Tek Corporation (NASDAQ: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that the Company will hold a conference call to discuss its fiscal second quarter and first half 2027 financial results, ended August 31, 2026, on Wednesday, October 14, 2026 at 10:30 am ET.

The second quarter and first half FY 2027 financial results press release will be issued before the market opens on October 14, 2026.

Conference Call Dial-in Information

To participate, please call 1-844-481-2752 or 1-412-317-0668 for international callers at least 10 minutes prior to the start of the call and ask to join the Sono-Tek call.

Webcast Information

A simultaneous webcast of the call may be accessed through the Company’s website, Events & Presentations | Sono-Tek or at:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=XwOIJQ1z

A replay of the call will be available at 1-855-669-9658 or 1-412-317-0088 for international callers, access code 9211789, through October 28, 2026. A replay of the call will also be available on the Company’s website for one year at www.sono-tek.com.

About Sono-Tek

Sono-Tek Corporation is the global leader in the design and manufacture of ultrasonic coating systems that are shaping industries and driving innovation worldwide. Our ultrasonic coating systems are used to apply thin films onto parts used in diverse industries including microelectronics, alternative energy, medical devices, advanced industrial manufacturing, and research and development sectors worldwide. Sono-Tek’s inroads into the clean energy sector are showing transformative results in next-gen solar cells, fuel cells, green hydrogen generation, and carbon capture applications. 

Our product line is rapidly evolving, transitioning from R&D to high-volume production machines with significantly higher average selling prices, showcasing our market leadership and adaptability. Our comprehensive suite of thin film coating solutions and application consulting services are expected to generate unparalleled results for our clients and help some of the world’s most promising companies achieve technological breakthroughs and bring them to the market. We strategically deliver our products to customers through a network of direct sales personnel, carefully chosen independent distributors, and experienced sales representatives, ensuring efficient market reach across diverse sectors around the globe.

Our solutions are environmentally friendly, efficient and highly reliable, and enable dramatic reductions in overspray, savings in raw material, water and energy usage and provide improved process repeatability, transfer efficiency, high uniformity and reduced emissions.

Sono-Tek’s growth strategy is focused on leveraging its innovative technologies, proprietary know-how, unique talent and experience, and global reach to further develop thin film coating technologies that enable better outcomes for its customers’ products and processes. For further information, visit www.sono-tek.com.

For more information, contact:

Sono-Tek Corp.
Stephen J. Bagley
Chief Financial Officer
Ph: (845) 795-2020
info@sono-tek.com

Investor Relations:
Kirin Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs

ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today provided an update on its strategy and progress to implement a suite of U.S. Food and Drug Administration (FDA) aligned New Approach Methodologies (NAMs) across its preclinical research and development programs, potentially enabling faster clinical advancement while significantly reducing animal testing. This strategic implementation positions VERAXA ahead of the FDA’s 2025 roadmap, which encourages the phased reduction and ultimate replacement of animal testing in favor of human-relevant, non-animal and non-clinical test methods for developing safe and effective therapies.

NAMs encompass a range of technologies, including cell-based assays, organ-on-chip systems, computational modeling and ex vivo tissue models, designed to more accurately predict human biological responses while reducing dependence on animal models. Beyond this regulatory alignment, the shift toward more sustainable and ethical research practices is also expected to reduce development costs and timelines, for example, by bypassing certain non-human primate (NHP) toxicology studies traditionally required ahead of clinical development.

“We see NAMs as not just a regulatory obligation, but also as a scientific opportunity,” said Christoph Erkel, Ph.D., Chief Scientific Officer of VERAXA. “We’ve been investing in translational, human-relevant model systems well ahead of the FDA’s 2025 roadmap, and we see this shift as beneficial and a win-win situation for both science and sustainability. Reducing our reliance on animal studies, particularly NHP toxicology testing, allows us to generate more clinically predictive data, move faster, and do so more efficiently and sustainably.”

VERAXA has been building a multi-layered panel of NAMs to characterize and de-risk its pipeline of BiTAC (bi-targeted tumor-associated cytotoxicity) based T cell engagers (BiTAC-TCEs), BiTAC-based antibody drug conjugates (BiTAC-ADCs) and bispecific antibody-drug conjugates (bsADCs) technologies. At the AACR Annual Meeting 2026, the Company presented initial data on its most advanced BiTAC-TCE program. In those studies, the candidate performed as intended in vitro and in vivo, attacking cancer cells that displayed both target molecules while sparing cells expressing only one of the two, with a safety profile that was superior, and efficacy that matched, a more traditional TCE, pointing to the possibility of a meaningfully improved therapeutic index. The in vitro results came from three-dimensional, cell line-derived spheroid models, which recapitulate solid tumor architecture more closely than two-dimensional culture. VERAXA has since generated new spheroid data demonstrating consistent predictivity of T cell engagement specificity across diverse cancer cell lines and validating the model for IND-enabling studies, further reinforcing this model’s translational value ahead of clinical development.

VERAXA further evaluated its lead BiTAC-TCE and bsADC candidates in an ex vivo panel of ten low-passage patient-derived xenograft models of non-small cell lung cancer, models that closely preserve the molecular characteristics, heterogeneity, and therapeutic response of the original tumors. Because these assays draw on tumor material from a small number of donor mice and can be split into many parallel patient samples, the panel required only about ten mice in total, versus an estimated 200 or more for comparable in vivo efficacy studies.

Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, while relevant controls, including commercial T cell engagers against non-expressed targets, showed only minimal activity, providing strong evidence that VERAXA’s dual-targeting approach extends beyond cell line models into clinically meaningful anti-tumor activity, validating the need for simultaneous dual-target engagement and reinforcing BiTAC as a next-generation approach to T cell redirection. This ex vivo platform demonstrates how VERAXA’s NAM strategy reduces both animal use and preclinical cycle time without compromising clinical relevance.

About VERAXA Biotech AG (NASDAQ: VRXA)

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based cancer therapeutics, powered by a suite of transformative technologies and guided by rigorous quality-by-design principles. The company is rapidly advancing its pipeline of conditionally active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs), and proprietary BiTAC formats into clinical development. Uniquely, VERAXA has implemented FDA-aligned New Approach Methodologies across all preclinical programs, enabling faster clinical advancement while reducing reliance on animal testing. Founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a world-renowned institution for pioneering life science research, VERAXA combines innovation with responsible research practices.

For regular updates about VERAXA Biotech, visit www.veraxa.com or follow us on LinkedIn, X (formerly known as Twitter) and Bluesky.

BiTAC® is a registered trademark of VERAXA Biotech GmbH.

Forward-looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events, or developments that VERAXA Biotech AG (the “Company”) intends, expects, plans, projects, believes, or anticipates will or may occur in the future are forward-looking statements, including the Company’s ability to utilize NAMS across its preclinical research and development programs to enable faster clinical advancement and the ability of its technological platform to produce transformative therapeutics. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this press release should be evaluated together with the many uncertainties that affect the Company’s business, particularly those identified or referenced in the risk factors section of the Company’s most recent Annual Report on Form 20-F and any subsequent reports on Form 6-K. These documents are available from the Securities and Exchange Commission, the Company website or from Company Investor Relations.

In addition, any information contained in this press release was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained in this press release and investors should not rely upon the information as current or accurate after the presentation date.

Attachment

• 20261007_VRXA_NAM_Strategy_FINAL

CONTACT: Contact
VERAXA Biotech AG – Corporate 
 Christoph Antz, Ph.D.
 Chief Executive Officer, Co-Founder
 investors@veraxa.com
 
For Media and Investors – U.S.
 Brandon Weiner
 ICR Healthcare
 VERAXA@icrhealthcare.com
 
For Media and Investors – EU
 Mario Brkulj
 investors@veraxa.com

LONDON, Oct. 07, 2026 (GLOBE NEWSWIRE) — Marex Group Limited (‘Marex’ or the ‘Group’; NASDAQ: MRX) today announces that Chair of the Board Robert Pickering has stepped down from the Group Board, having overseen an exceptional period of growth and change during his appointed three-year term.

Robert joined the Group Board in September 2021 before becoming Senior Independent Director in March 2022 and Chair of the Board in October 2023. During Robert’s tenure, Marex has undergone a period of significant growth and transformation, including its successful IPO in April 2024, and development into a leading diversified global financial services platform.

Robert has been succeeded as Chair by John Pietrowicz, a current member of the Board and Chair of the Group’s Mergers and Acquisitions Committee. John joined the Group Board in April 2024, having previously served as Chief Financial Officer of CME Group from 2014 until 2023. His extensive experience at CME, including overseeing its acquisition strategy, brings valuable expertise in financial markets infrastructure and M&A. He is also a well-known figure to the Group’s analysts and investor base. John will work closely with Robert to ensure a smooth transition.

Robert Pickering, outgoing Chair: “It has been fascinating to be part of Marex’s progression over the past five years, helping it evolve from a small private company into a Nasdaq-listed business with a market capitalization in excess of $5 billion. Marex has exciting prospects and I wish it every success in the future.”

Ian Lowitt, Group CEO: “On behalf of the Board and everyone at Marex, I would like to thank Robert for his outstanding contribution. Marex has been on an incredible journey and Robert’s experience, judgment and counsel have been invaluable. Robert guided the firm through the listing process, successful IPO on Nasdaq, and subsequent diversification and growth. We are grateful for his leadership and commitment to Marex and wish him all the very best for the future. I am excited to work with John as our new Chair as we embark on our next chapter and as we seek to extend our track record of sustainable growth.”  

About Marex: Marex Group Limited (NASDAQ: MRX) provides market access, infrastructure services and essential liquidity to clients across global commodity and financial markets. The Group provides comprehensive breadth and depth of coverage across four services: Clearing, Agency and Execution, Market Making and Hedging and Investment Solutions. It has a leading franchise in many major metals, energy and agricultural products, with access to more than 60 exchanges. Marex has over 3,400 active clients, including some of the largest commodity producers, consumers and traders, banks, hedge funds and asset managers. With more than 50 offices worldwide, the Group has over 3,000 employees across Europe, Asia and the Americas. For more information visit www.marex.com.

Enquiries please contact:
Marex: Nicola Ratchford / Adam Strachan
+44 778 654 8889 / +1 914 200 2508
nratchford@marex.com / astrachan@marex.com

FTI Consulting US / UK
+1 716 525 7239 / +44 7976870961
marex@fticonsulting.com

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the board changes and the future growth of the business. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “would,” “is/are likely to” or other similar expressions.

These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the risks discussed under the caption “Risk Factors” in our Annual Report on Form 20-F for the year-ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) and our other reports filed with the SEC. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.